Fortis Group Advisors LLC Buys 500 Shares of Bristol-Myers Squibb (NYSE:BMY)

Fortis Group Advisors LLC grew its stake in Bristol-Myers Squibb (NYSE:BMY) by 14.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,984 shares of the biopharmaceutical company’s stock after acquiring an additional 500 shares during the period. Fortis Group Advisors LLC’s holdings in Bristol-Myers Squibb were worth $204,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BMY. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $34,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth about $40,000. Wetzel Investment Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Finally, VisionPoint Advisory Group LLC raised its position in Bristol-Myers Squibb by 300.5% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 553 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Down 0.7 %

NYSE BMY traded down $0.28 on Friday, reaching $41.20. The stock had a trading volume of 14,271,103 shares, compared to its average volume of 14,094,110. Bristol-Myers Squibb has a 12-month low of $39.91 and a 12-month high of $66.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock has a fifty day moving average price of $44.50 and a two-hundred day moving average price of $48.73. The firm has a market capitalization of $83.52 billion, a price-to-earnings ratio of -13.29, a P/E/G ratio of 14.04 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same period last year, the firm earned $2.05 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of recent research reports. Barclays reduced their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 23rd. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.